Through our Organizational Regulations, the Board of Directors has delegated the responsibility and authority necessary or appropriate for carrying out the day-to-day and operational activities of PolyPeptide to the Executive Committee under the leadership of the CEO.

The CEO is accountable for the sustainable management and results-oriented performance of the Group. As such, the CEO leads, manages, supervises and coordinates the Executive Committee and the PMC as well as executes the corporate goals and strategy as set by the Board of Directors. The detailed responsibilities and functions of the Executive Committee, including the CEO and the CFO, are described in section 6 of the Organizational Regulations.

In general, meetings of the Executive Committee take place as determined by the CEO, with the expectation that there be no fewer than six such meetings per calendar year (as provided for in the Organizational Regulations). For the year ended 31 December 2025, the Executive Committee formally met seven (7) times, in a combination of in-person sessions and video conferences, for an average duration of approximately one and a half (1.5) hours. The resolutions of the Executive Committee are taken by the majority of the members of the Executive Committee present, where the CEO has the power to overrule any Executive Committee resolution. The Organizational Regulations set forth procedures to address conflicts of interest.

4.1Members of the Executive Committee

As of 31 December 2025, the Executive Committee comprised the CEO, CFO, Chief Manufacturing and Supply Chain Officer and the Chief Legal Officer. Jens Fricke stepped down as Director Global Operations and from the Executive Committee as of 10 August 2025.¹⁴ The year of appointment in the table below reflects each Executive Committee member’s respective appointment in their current position with the Group (including at Group subsidiaries).

Set out below is a short description of the business experience, education and activities for each Executive Committee member in office as of 31 December 2025.

Juan Jose Gonzalez

Chief Executive Officer

Nationality:Peruvian and American

Year of birth:1972

Professional background

Functions at PolyPeptide

• Chief Executive Officer (since 2023)
• Chair / Member of the board of directors of several PolyPeptide subsidiaries (since 2023)

Outside mandates at listed / non-listed companies or non-profit organizations

• None

Former outside activities and functions

• Member of the board of directors and Member of the Audit & Remuneration Committee, Straumann Group, Switzerland (2019–2024)
• Chief Executive Officer, Ambu, Denmark (2019–2022)
• Various senior roles within the Johnson & Johnson Group, US (2007–2019), including Global Vice President, Smoking Cessation, OTC division, UK, (2007), Area Managing Director, Consumer sector, United Kingdom (2011–2013) and ultimately serving as President Orthopeadics, Medical Devices sector, US (2016–2019)
• Commercial Director Europe, Middle East and Africa, Pfizer Inc. Consumer Healthcare Division, UK, (2004–2006)

Education

• Master of Technology Management, Columbia University, New York, US (2016)
• MBA in Marketing and Corporate Finance, University of Notre Dame, US (1999)
• Bachelor of Science in Industrial Engineering, University of Lima, Peru (1993)

Read More

Christina Del Vecchio

Chief Legal Officer

Nationality:Swiss and Swedish

Year of birth:1978

Professional background

Functions at PolyPeptide

• Chief Legal Officer and Corporate Secretary (since 2025)
• General Counsel and Corporate Secretary (2021–2024)
• Member of the board of directors of a PolyPeptide subsidiary (since 2023)

Outside mandates at listed / non-listed companies or non-profit organizations

• None

Former outside activities and functions

• Counsel, Niederer Kraft Frey AG, Switzerland (2018–2021)
• Senior Associate, Niederer Kraft Frey AG, Switzerland (2013–2018)
• Associate, Latham & Watkins LLP, United Kingdom (2008–2012)

Education

• Juris Doctor, James Kent Scholar, Columbia Law School, US (2008)
• Bachelor of Arts, summa cum laude, University of Florida, US (2000)

Read More

Marc Augustin

Chief Financial Officer

Nationality:German and Swiss

Year of birth:1972

Professional background

Functions at PolyPeptide

• Chief Financial Officer (since 2024)¹⁵
• Member of the board of directors of several PolyPeptide subsidiaries (since 2025)

Outside mandates at listed / non-listed companies or non-profit organizations

• None

Former outside activities and functions

• Various senior roles at Lonza AG, Switzerland (2016–2023), including Vice President Finance Biologics (2020-2022) and Global Head Sales Excellence Biologics (2022–2023)
• Various senior roles at Smith & Nephew Orthopaedics AG, Switzerland (2009–2016), including Head of Finances Operations Orthopaedics Europe (2013–2016) and Finance Director Switzerland (2009–2013)
• Head of Finance, Alcoa Extrusion Hannover GmbH & CO. KG, Germany (2008–2009)

Education

• MBA in Controlling, Tax, Heinrich-Heine-Universität Düsseldorf, Germany (1998)

Read More

15Marc Augustin resigned as CFO and member of the Executive Committee effective 31 March 2026.

Raoul Bernhardt

Chief Manufacturing and Supply Chain Officer

Nationality:French

Year of birth:1970

Professional background

Functions at PolyPeptide

• Chief Manufacturing and Supply Chain Officer (since 2025)
• Member of the board of directors of several PolyPeptide subsidiaries (since 2025)

Outside mandates at listed / non-listed companies or non-profit organizations

• None

Former outside activities and functions

• Senior Vice President Technical Operations, Guerbet, France (2023–2025)
• Various senior roles at Catalent Pharma Solutions, France and Germany (2014–2023), including Vice-President Operations, Pharma Product Delivery Division (2022–2023), Regional General Manager Europe and APAC (2021–2022)

Education

• Master of Sciences in Supply Chain Management from Strasbourg Management School, France (2008)

Read More

In 2025, the Executive Committee, under the leadership of the CEO, was further supported by additional members of management, that, together with the Executive Committee, formed the PMC.

4.2Other activities and vested interests

Except as disclosed in the biographies of the members of the Executive Committee, no further activities or vested interests are carried out outside of PolyPeptide.

4.3Mandates and other permitted activities

In accordance with Swiss law, our Articles of Association limit the number of functions in superior management or administrative bodies of legal units other than with PolyPeptide that members of the Executive Committee are allowed to hold at one time.

Pursuant to art. 23 of the Articles of Association, with the approval of the Board of Directors, the members of the Executive Committee may have the following comparable functions at other companies with an economic purpose (including their group):

• up to one (1) mandate as member of the board of directors or any other superior management or administrative body of listed companies; and, in addition,
• up to five (5) mandates as member of the board of directors or any other superior management or administrative body of other legal entities that do not meet the above mentioned criteria.

With respect to the additional activities of the members of the Executive Committee, mandates in companies that are under uniform control or the same beneficial ownership are deemed to be one mandate.

The following mandates shall not be subject to the limitations set forth in art. 23 of the Articles of Association:

• mandates in companies which are controlled by the Company or which control the Company;
• mandates held at the request of the Company or companies controlled by it; no member of the Executive Committee shall, however, hold more than ten (10) such mandates; and
• mandates in associations, charitable organizations, foundations, employee welfare foundations and other similar organizations; no member of the Executive Committee shall, however, hold more than fifteen (15) such mandates.

4.4Management contracts

The Company and its subsidiaries have not entered into any management contracts with third parties.

4.5Gender guidelines

As of 31 December 2025, one (1) out of four (4) members of the Executive Committee was female (25%). The RNC, together with the Board of Directors, actively considers gender diversity in succession planning of the Executive Committee.